Amicus Therapeutics Inc.

8.77-0.0600-0.68%Vol 964.42K1Y Perf -42.21%
Jul 27th, 2021 14:08 DELAYED
BID8.77 ASK8.78
Open8.79 Previous Close8.83
Pre-Market8.82 After-Market-
 -0.01 -0.11%  - -
Target Price
18.05 
Analyst Rating
Strong Buy 1.22
Potential %
105.11 
Finscreener Ranking
★★+     47.97
Insiders Trans % 3/6/12 mo.
-56/-58/-56 
Value Ranking
     40.22
Insiders Value % 3/6/12 mo.
-95/-94/-94 
Growth Ranking
★★     44.43
Insiders Shares Cnt. % 3/6/12 mo.
-94/-94/-95 
Income Ranking
 —    -
Market Cap2.33B 
Earnings Rating
Sell
Price Range Ratio 52W %
1.01 
Earnings Date
9th Aug 2021

Today's Price Range

8.648.93

52W Range

8.6025.39

5 Year PE Ratio Range

-4.50-7.90

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-7.25%
1 Month
-14.93%
3 Months
-12.49%
6 Months
-53.48%
1 Year
-42.21%
3 Years
-40.70%
5 Years
23.84%
10 Years
31.01%

TickerPriceChg.Chg.%
FOLD8.77-0.0600-0.68
AAPL146.14-2.8500-1.91
GOOG2 706.16-86.7300-3.11
MSFT284.30-4.7500-1.64
XOM57.55-0.9300-1.59
WFC45.040.03000.07
JNJ172.320.45000.26
FB365.87-6.5900-1.77
GE13.060.14001.08
JPM151.63-0.0200-0.01
Financial StrengthValueIndustryS&P 500US Markets
4.60
5.00
0.63
1.76
-8.40
Leverage Ratio 3.20
ProfitabilityValueIndustryS&P 500US Markets
88.40
-83.60
-80.40
-1 201.90
-98.37
RevenueValueIndustryS&P 500US Markets
204.41M
0.77
52.15
-
Earnings HistoryEstimateReportedSurprise %
Q01 2021-0.23-0.25-8.70
Q04 2020-0.24-0.27-12.50
Q03 2020-0.20-0.22-10.00
Q02 2020-0.26-0.2023.08
Q01 2020-0.28-0.35-25.00
Q04 2019-0.26-0.35-34.62
Q03 2019-0.32-0.2425.00
Q02 2019-0.34-0.340.00
Earnings Per EndEstimateRevision %Trend
6/2021 QR-0.21-5.00Negative
9/2021 QR-0.21-16.67Negative
12/2021 FY-0.812.41Positive
12/2022 FY-0.38-8.57Negative
Next Report Date9th Aug 2021
Estimated EPS Next Report-0.21
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume964.42K
Shares Outstanding266.06M
Trades Count7.61K
Dollar Volume57.49M
Avg. Volume3.21M
Avg. Weekly Volume1.75M
Avg. Monthly Volume2.15M
Avg. Quarterly Volume2.42M

Amicus Therapeutics Inc. (NASDAQ: FOLD) stock closed at 8.83 per share at the end of the most recent trading day (a 0.11% change compared to the prior day closing price) with a volume of 1.71M shares and market capitalization of 2.33B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 584 people. Amicus Therapeutics Inc. CEO is John F. Crowley.

The one-year performance of Amicus Therapeutics Inc. stock is -42.21%, while year-to-date (YTD) performance is -61.76%. FOLD stock has a five-year performance of 23.84%. Its 52-week range is between 8.6 and 25.39, which gives FOLD stock a 52-week price range ratio of 1.01%

Amicus Therapeutics Inc. currently has a PE ratio of -9.10, a price-to-book (PB) ratio of 9.35, a price-to-sale (PS) ratio of 11.48, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -32.75%, a ROC of -36.60% and a ROE of -77.60%. The company’s profit margin is -98.37%, its EBITDA margin is -80.40%, and its revenue ttm is $204.41 Million , which makes it $0.77 revenue per share.

Of the last four earnings reports from Amicus Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.21 for the next earnings report. Amicus Therapeutics Inc.’s next earnings report date is 09th Aug 2021.

The consensus rating of Wall Street analysts for Amicus Therapeutics Inc. is Strong Buy (1.22), with a target price of $18.05, which is +105.11% compared to the current price. The earnings rating for Amicus Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Amicus Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Amicus Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 31.13, ATR14 : 0.39, CCI20 : -111.63, Chaikin Money Flow : -0.09, MACD : -0.26, Money Flow Index : 62.32, ROC : -5.96, RSI : 39.37, STOCH (14,3) : 20.91, STOCH RSI : 0.16, UO : 41.21, Williams %R : -79.09), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Amicus Therapeutics Inc. in the last 12-months were: Bradley L. Campbell (Option Excercise at a value of $505 920), Bradley L. Campbell (Sold 52 570 shares of value $643 770 ), Burke W. Whitman (Buy at a value of $126 707), Daphne Quimi (Option Excercise at a value of $48 886), John F. Crowley (Option Excercise at a value of $802 873), John F. Crowley (Sold 257 432 shares of value $3 584 975 ), Margaret G. McGlynn (Option Excercise at a value of $75 100), Margaret G. McGlynn (Sold 10 000 shares of value $102 704 ), Michael G. Raab (Option Excercise at a value of $42 593)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
8 (88.89 %)
8 (88.89 %)
8 (88.89 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (11.11 %)
1 (11.11 %)
1 (11.11 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.22
Strong Buy
1.22
Strong Buy
1.22

Amicus Therapeutics Inc.

Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Currently, the company is focused on treating Fabry Disease with its treatment Galafold and developing additional therapies for Fabry patients. Amicus has also received breakthrough therapy designation that allows it to deploy a therapy for Pompe Disease in late-stage patients.

CEO: John F. Crowley

Telephone: +1 609 662-2000

Address: 1 Cedar Brook Drive, Cranbury 08512, NJ, US

Number of employees: 584

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

25%75%

Bearish Bullish

57%43%

Bearish Bullish

62%38%

News

Stocktwits